Breaking News

Cobra Biologics, Vaccibody in DNA Vax-Pact

Cobra to supply clinical trials materials

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Cobra Biologics and Vaccibody have entered an agreement to manufacture Vaccibody’s lead DNA vaccine candidate against HPV-induced malignancies, such as precancerous lesions found in cervical cancer. Cobra Biologics will apply its platform process to deliver a program of host strain generation, GMP cell banking, plasmid DNA production and clinical trials supply.   Vaccibody develops targeted vaccines designed to induce stronger and longer lasting immune responses using its technology platform for...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters